Management raised its full-year forecast, but the market seems to be asking for more than a higher target.

On Aug 4, 2026, Amgen (AMGN)’s management did what investors love to see: they raised their full-year revenue guidance. It’s a public declaration of confidence, a signal that the business is humming. Yet, if you owned the stock hoping for a celebratory pop, you might be feeling a little underwhelmed. The share price has been climbing, but it hasn’t broken decisively out of its recent range. This sets up a fascinating standoff. Management is pointing to a brighter future, but the market seems to be saying, We’ve already paid for that. Now show us the next act.

What’s Behind That New Revenue…